Research ExplorerPublicationsPrevalence of CD8+ cytotoxic lymphocytes in human neoplasms

Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms

Standard

Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. / Blessin, Niclas C; Spriestersbach, Patrick; Li, Wenchao; Mandelkow, Tim; Dum, David; Simon, Ronald; Hube-Magg, Claudia; Lutz, Florian; Viehweger, Florian; Lennartz, Maximillian; Fraune, Christoph; Nickelsen, Vera; Fehrle, Wilfried; Göbel, Cosima; Weidemann, Sören; Clauditz, Till; Lebok, Patrick; Möller, Katharina; Steurer, Stefan; Izbicki, Jacob R; Sauter, Guido; Minner, Sarah; Jacobsen, Frank; Luebke, Andreas M; Büscheck, Franziska; Höflmayer, Doris; Wilczak, Waldemar; Burandt, Eike; Hinsch, Andrea.

In: CELL ONCOL, Vol. 43, No. 3, 06.2020, p. 421-430.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Blessin, NC, Spriestersbach, P, Li, W, Mandelkow, T, Dum, D, Simon, R, Hube-Magg, C, Lutz, F, Viehweger, F, Lennartz, M, Fraune, C, Nickelsen, V, Fehrle, W, Göbel, C, Weidemann, S, Clauditz, T, Lebok, P, Möller, K, Steurer, S, Izbicki, JR, Sauter, G, Minner, S, Jacobsen, F, Luebke, AM, Büscheck, F, Höflmayer, D, Wilczak, W, Burandt, E & Hinsch, A 2020, 'Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms', CELL ONCOL, vol. 43, no. 3, pp. 421-430. https://doi.org/10.1007/s13402-020-00496-7

APA

Blessin, N. C., Spriestersbach, P., Li, W., Mandelkow, T., Dum, D., Simon, R., Hube-Magg, C., Lutz, F., Viehweger, F., Lennartz, M., Fraune, C., Nickelsen, V., Fehrle, W., Göbel, C., Weidemann, S., Clauditz, T., Lebok, P., Möller, K., Steurer, S., ... Hinsch, A. (2020). Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. CELL ONCOL, 43(3), 421-430. https://doi.org/10.1007/s13402-020-00496-7

Vancouver

Blessin NC, Spriestersbach P, Li W, Mandelkow T, Dum D, Simon R et al. Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. CELL ONCOL. 2020 Jun;43(3):421-430. https://doi.org/10.1007/s13402-020-00496-7

Bibtex

@article{7e761e5de92a4601ab70aaf341c12770,
title = "Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms",
abstract = "PURPOSE: Immune checkpoint inhibitors have recently been approved by the US FDA as first and/or second line therapy in a subset of cancer types. Recent evidence suggests that the quantity of tumor infiltrating lymphocytes (TILs) influences the likelihood of response to immune checkpoint inhibitors. Here, we set out to assess the density of CD8+ lymphocytes in a wide range of different cancer types and subtypes.METHODS: The density of CD8+ lymphocytes was compared across different cancer types using tissue microarrays (TMAs) composed of up to 50 tumor samples each from 84 different cancer types and subtypes. In total 2652 cancers and 608 normal tissues were successfully analyzed by CD8 immunohistochemistry followed by automated image analysis of digitized slides.RESULTS: We found that the median CD8+ lymphocyte counts ranged from 6 cells/mm2 in pleomorphic adenoma up to 1573 cells/mm2 in Hodgkin's lymphoma. The CD8 counts were generally lower in normal tissues compared to cancer tissues. Blood vessels of the spleen were the only non-lymphatic tissue staining positive for CD8. Tumor types approved for checkpoint inhibitor therapy, including malignant melanoma (81), muscle invasive urothelial carcinoma (119), small cell lung cancer (120), clear cell renal cell cancer (153), squamous cell carcinoma (189) and adenocarcinoma of the lung (328) as well as Hodgkin's lymphoma (1573) were all ranking among the upper half of our list. Comparably high CD8 densities (median cells/mm2) were also found in several rare and aggressive cancer types including Merkel cell carcinoma (70), angiosarcoma (95), anaplastic thyroid cancer (156) and embryonal carcinoma of the testis (186). In 73 of the 84 analyzed cancer types, the highly variable CD8 counts occasionally exceeded the average CD8 count of tumors for which checkpoint inhibitors have been approved.CONCLUSION: These data support the concept that among most tumor types at least some individual cancers may benefit from treatment with immune checkpoint inhibitors.",
author = "Blessin, {Niclas C} and Patrick Spriestersbach and Wenchao Li and Tim Mandelkow and David Dum and Ronald Simon and Claudia Hube-Magg and Florian Lutz and Florian Viehweger and Maximillian Lennartz and Christoph Fraune and Vera Nickelsen and Wilfried Fehrle and Cosima G{\"o}bel and S{\"o}ren Weidemann and Till Clauditz and Patrick Lebok and Katharina M{\"o}ller and Stefan Steurer and Izbicki, {Jacob R} and Guido Sauter and Sarah Minner and Frank Jacobsen and Luebke, {Andreas M} and Franziska B{\"u}scheck and Doris H{\"o}flmayer and Waldemar Wilczak and Eike Burandt and Andrea Hinsch",
year = "2020",
month = jun,
doi = "10.1007/s13402-020-00496-7",
language = "English",
volume = "43",
pages = "421--430",
journal = "CELL ONCOL",
issn = "2211-3428",
publisher = "Springer Netherlands",
number = "3",

}

RIS

TY - JOUR

T1 - Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms

AU - Blessin, Niclas C

AU - Spriestersbach, Patrick

AU - Li, Wenchao

AU - Mandelkow, Tim

AU - Dum, David

AU - Simon, Ronald

AU - Hube-Magg, Claudia

AU - Lutz, Florian

AU - Viehweger, Florian

AU - Lennartz, Maximillian

AU - Fraune, Christoph

AU - Nickelsen, Vera

AU - Fehrle, Wilfried

AU - Göbel, Cosima

AU - Weidemann, Sören

AU - Clauditz, Till

AU - Lebok, Patrick

AU - Möller, Katharina

AU - Steurer, Stefan

AU - Izbicki, Jacob R

AU - Sauter, Guido

AU - Minner, Sarah

AU - Jacobsen, Frank

AU - Luebke, Andreas M

AU - Büscheck, Franziska

AU - Höflmayer, Doris

AU - Wilczak, Waldemar

AU - Burandt, Eike

AU - Hinsch, Andrea

PY - 2020/6

Y1 - 2020/6

N2 - PURPOSE: Immune checkpoint inhibitors have recently been approved by the US FDA as first and/or second line therapy in a subset of cancer types. Recent evidence suggests that the quantity of tumor infiltrating lymphocytes (TILs) influences the likelihood of response to immune checkpoint inhibitors. Here, we set out to assess the density of CD8+ lymphocytes in a wide range of different cancer types and subtypes.METHODS: The density of CD8+ lymphocytes was compared across different cancer types using tissue microarrays (TMAs) composed of up to 50 tumor samples each from 84 different cancer types and subtypes. In total 2652 cancers and 608 normal tissues were successfully analyzed by CD8 immunohistochemistry followed by automated image analysis of digitized slides.RESULTS: We found that the median CD8+ lymphocyte counts ranged from 6 cells/mm2 in pleomorphic adenoma up to 1573 cells/mm2 in Hodgkin's lymphoma. The CD8 counts were generally lower in normal tissues compared to cancer tissues. Blood vessels of the spleen were the only non-lymphatic tissue staining positive for CD8. Tumor types approved for checkpoint inhibitor therapy, including malignant melanoma (81), muscle invasive urothelial carcinoma (119), small cell lung cancer (120), clear cell renal cell cancer (153), squamous cell carcinoma (189) and adenocarcinoma of the lung (328) as well as Hodgkin's lymphoma (1573) were all ranking among the upper half of our list. Comparably high CD8 densities (median cells/mm2) were also found in several rare and aggressive cancer types including Merkel cell carcinoma (70), angiosarcoma (95), anaplastic thyroid cancer (156) and embryonal carcinoma of the testis (186). In 73 of the 84 analyzed cancer types, the highly variable CD8 counts occasionally exceeded the average CD8 count of tumors for which checkpoint inhibitors have been approved.CONCLUSION: These data support the concept that among most tumor types at least some individual cancers may benefit from treatment with immune checkpoint inhibitors.

AB - PURPOSE: Immune checkpoint inhibitors have recently been approved by the US FDA as first and/or second line therapy in a subset of cancer types. Recent evidence suggests that the quantity of tumor infiltrating lymphocytes (TILs) influences the likelihood of response to immune checkpoint inhibitors. Here, we set out to assess the density of CD8+ lymphocytes in a wide range of different cancer types and subtypes.METHODS: The density of CD8+ lymphocytes was compared across different cancer types using tissue microarrays (TMAs) composed of up to 50 tumor samples each from 84 different cancer types and subtypes. In total 2652 cancers and 608 normal tissues were successfully analyzed by CD8 immunohistochemistry followed by automated image analysis of digitized slides.RESULTS: We found that the median CD8+ lymphocyte counts ranged from 6 cells/mm2 in pleomorphic adenoma up to 1573 cells/mm2 in Hodgkin's lymphoma. The CD8 counts were generally lower in normal tissues compared to cancer tissues. Blood vessels of the spleen were the only non-lymphatic tissue staining positive for CD8. Tumor types approved for checkpoint inhibitor therapy, including malignant melanoma (81), muscle invasive urothelial carcinoma (119), small cell lung cancer (120), clear cell renal cell cancer (153), squamous cell carcinoma (189) and adenocarcinoma of the lung (328) as well as Hodgkin's lymphoma (1573) were all ranking among the upper half of our list. Comparably high CD8 densities (median cells/mm2) were also found in several rare and aggressive cancer types including Merkel cell carcinoma (70), angiosarcoma (95), anaplastic thyroid cancer (156) and embryonal carcinoma of the testis (186). In 73 of the 84 analyzed cancer types, the highly variable CD8 counts occasionally exceeded the average CD8 count of tumors for which checkpoint inhibitors have been approved.CONCLUSION: These data support the concept that among most tumor types at least some individual cancers may benefit from treatment with immune checkpoint inhibitors.

U2 - 10.1007/s13402-020-00496-7

DO - 10.1007/s13402-020-00496-7

M3 - SCORING: Journal article

C2 - 32141029

VL - 43

SP - 421

EP - 430

JO - CELL ONCOL

JF - CELL ONCOL

SN - 2211-3428

IS - 3

ER -